BTIG analyst Sean Lavin maintained a Hold rating on Intersect ENT (NASDAQ: XENT) yesterday. The company’s shares closed yesterday at $40, close to its 52-week high of $42.25.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 14.9% and a 63.3% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Accelerate Diagnostics.
Intersect ENT has an analyst consensus of Moderate Buy, with a price target consensus of $41.20.
Find more picks by Best Performing Analysts >>
The company has a one-year high of $42.25 and a one-year low of $20.35. Currently, Intersect ENT has an average volume of 239.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intersect ENT, Inc. is a medical technology company, which is dedicated in the treatment of ear, nose, and throat conditions through evidence-based innovation, providing physicians with solutions to improve quality of life for patients. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.
